Key facts
- This page summarizes Sanofi's Form 3 filing for MeiraGTx Holdings plc (MGTX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2024, 06:30.
Sanofi - 12 Aug 2024 Form 3 Insider Report for MeiraGTx Holdings plc (MGTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MGTX
- Reported as of
- 12 Aug 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 13 Aug 2024, 06:30:03 UTC
- Prior SEC filing
- 14 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexandra Roger, Alexandra Roger, Head of Legal Corporate & Finance
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sanofi filed Form 3 for MeiraGTx Holdings plc (MGTX) on 13 Aug 2024.
Change
- Previous filing in this sequence was filed on 14 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MGTX
holding
Ordinary Shares ($0.00003881 par value per share)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,500,000
- Date
- 12 Aug 2024
- Ownership
- Through its wholly-owned subsidiary, Sanofi Foreign Participations B.V.
- Footnotes
- F1
MGTX
holding
Ordinary Shares ($0.00003881 par value per share)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 697,737
- Date
- 12 Aug 2024
- Ownership
- Through its wholly-owned subsidiary Kadmon Corporation, LLC
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Sanofi is the beneficial owner of Ordinary Shares of the Issuer through its wholly owned subsidiaries Sanofi Foreign Participations B.V. and Kadmon Corporation, LLC.